NetworkNewsBreaks Archive - Page 1907 of 1979

FridayMar 31, 2017 11:46 am

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Releases Financial Results for Full Year, Fourth Quarter of 2016

Health care information technology company Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) this morning reported its financial results for both the full year and fourth quarter of 2016. Among the highlights, the company reported revenue of $8.8 million for the three-month period, representing a hefty year-over-year increase of 65 percent. “We are pleased to announce 65% revenue growth over the fourth quarter of 2015 as well as 65% growth over the third quarter of 2016, and our third consecutive quarter of quarter-over-quarter revenue growth,” Mahmud Haq, chairman and CEO of MTBC, stated in the news release. “We are greatly encouraged…

FridayMar 31, 2017 11:18 am

NetworkNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Prices $4.5M Public Offering; Shares Drop

Shares of DarioHealth (NASDAQ: DRIO) dropped 22% in morning trade after the company released the pricing of an underwritten public offering of 1,450,000 shares of its common stock at a public offering price of $3.10 per share. Gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $4.5 million. Dario intends to use the net proceeds toward commercialization efforts of its products and for general working capital purposes. Subject to customary closing conditions, the offering is expected to close on April 5, 2017. To view the full press release,…

FridayMar 31, 2017 11:16 am

NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Shares Higher on New Patents Protecting BELBUCA®, BUNAVAIL® and ONSOLIS®

BioDelivery Sciences (NASDAQ: BDSI) shares are up 7% after the company this morning said that it has received two new patents further strengthening BDSI's overall intellectual property position. The new patents protect all three of its FDA-approved products: BELBUCA® buccal film, BUNAVAIL® buccal film, and ONSOLIS®. One patent covers the composition of the BioErodible MucoAdhesive (BEMA®) drug delivery technology, which provides additional patent coverage for BELBUCA and BUNAVAIL to July 2027 and will be listed in the Orange Book. The second patent, also to be listed in the Orange Book, extends protection on ONSOLIS from January 2020 to July 2027.…

ThursdayMar 30, 2017 1:21 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on March 30, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VBIO 29.41% – News: Reports positive results indicating a new use for delivery platform ACST 13.49% – News: Issues update on CaPre phase 3 development program UNXL 13.13% – News: Awarded tablet program by major Japan-based PC manufacturer OBMP 11.86% – News: Finalizes partnership terms with Gem Pharmaceuticals to develop new cancer drug WSTL 11.68% – News: Presenting at VirtualInvestorConferences.com on April 6 KSHB 11.36% – News: Presenting at VirtualInvestorConferences.com on April 6 FTMR…

ThursdayMar 30, 2017 1:15 pm

NetworkNewsBreaks – ProBility Media Corp. (PBYA) on Par with Skilled Trade Market; Develops Technical Training Brand For Over 60 Skilled Professions

The field for technical training is ripe, as the Bureau of Labor Statistics (BLS) forecasts continued growth for skilled trades. ProBility Media (OTCQB: PBYA) is a growing educational technology company developing the first full service training and career advancement brand for technical vocations and trades – right on par with the demand for career advancement for technical vocations and trades. “ProBility is the only company building the full spectrum of career training, advancement and compliance tools for tradesmen and technical experts in a wide variety of over 60 skilled professions. ProBility is executing a disruptive strategy of defragmenting the marketplace…

ThursdayMar 30, 2017 1:11 pm

NetworkNewsBreaks – Moxian (NASDAQ: MOXC) Anticipated to Reach Revenues of Over $62M in 2020

SeeThruEquity recently issued a research report on Moxian (NASDAQ: MOXC) which estimates sales of more than $62 million and a gross profit of more than $39 million in FY 2020 (http://nnw.fm/T6Aj4). “In the O2O market, online consumers are attracted to brick and mortar stores through various incentives. Moxian is expected to launch its paid Moxian+ platform this year. To the 75 million small- and medium-sized businesses in China, Moxian will offer its premium services for a fee. Services on its Moxian+ Business App would include access to analytics, hosting of online shops, targeted marketing, and the ability to host social…

ThursdayMar 30, 2017 1:08 pm

NetworkNewsBreaks – Tonix Pharmaceuticals (NASDAQ: TNXP) Prices Public Offering, Initiates Enrollment in HONOR Study

Tonix Pharmaceuticals (NASDAQ: TNXP) this morning released the pricing of an underwritten public offering of 1,800,000 shares of its common stock at a public offering price of $4.45 per share, for estimated gross proceeds of $8,010,000. The offering is expected to close on or about April 4, 2017, subject to customary closing conditions. Tonix intends to use the net proceeds for many projects, including the further development of pipeline programs, working capital and other general purposes, and to support the continued development of TNX-102 SL. Yesterday, Tonix said that Seth Lederman, M.D., president and chief executive officer will provide a…

ThursdayMar 30, 2017 11:28 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $8 PT on Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Aegis Capital has reiterated its ‘Buy’ rating and price target of $8 on Matinas BioPharma (NYSE: MTNB). Aegis cited positive results from the company’s phase 1 clinical trial of the safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin used to treat different types of chronic and acute bacterial infections. Although mild adverse events on the gastrointestinal system were reported, they decreased when the drug was administered with food. No serious adverse events were reported. Aegis also noted recent, critical comments posted to a financial website, which the analyst believes to be incorrect and responsible for recent volatility…

ThursdayMar 30, 2017 11:13 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Invests in Breakwater MB, LLC

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company formed by CIIX board member and former CFO Paul Dickman. CIIX’s initial investment into Breakwater MB will total $250,000, with the company maintaining an option to make additional investments at its own election. Per the news release, Breakwater MB intends to use the invested capital primarily to cover the costs of becoming a publicly traded company. CIIX management expects that this strategy will provide significant investment appreciate and opportunity for liquidity. “With the gradual opening up of the…

ThursdayMar 30, 2017 10:33 am

NetworkNewsBreaks – MySize (NASDAQ: MYSZ) Trades Higher on Commercial Phase of KatzID Development

MySize (NASDAQ: MYSZ) shares are up 19% this morning after the company said it has completed the beta-pilot testing phase and has initiated the commercial phase of KatzID, a courier measurement application developed by MySize. KatzID will enable employees of Katz Corporation to easily and quickly measure the size of a parcel and calculate its exact shipping cost. The application also delivers barcode scanning, package pictures, location and more, which connect to Katz' ERP system to better manage their delivery processes. "Today marks a major milestone in the development of a very important product that is going to significantly improve…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks